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Abstract
The use of image- and performance-enhancing drugs particularly anabolic-androgenic
steroids (AAS) is not a new phenomenon. AAS use is not limited to athletes, with
mainstream populations using these drugs for aesthetic purposes. Prevalence has been
predominantly in Western countries, with some recent studies indicating a rise in popu-
larity in the Eastern Mediterranean region. A scoping review of extant empirical literature
from the Eastern Mediterranean region described and mapped what is known about the
extent of AAS in the region. Four themes emerged from the review: (1) profile of AAS
users; (2) AAS within gymnasium practice; (3) AAS regimes of use; and (4) knowledge
and understanding of the AAS concept and related adverse effects. The review highlights
a relatively new phenomenon of AAS use in the Eastern Mediterranean. The review
underscores the need to carry out further research, particularly qualitative and quantitative
studies with both genders, and cognisant of the complexities of culture and religiosity.
Keywords Anabolic steroids . EasternMediterranean . Gym users . Image- and performance-
enhancing drugs
The use of image- and performance-enhancing drugs (IPEDs) particularly anabolic-androgenic
steroids (AAS) is not a new phenomenon (Dimeo 2007; Hoberman 2001; Yesalis 2001; Zahnow
et al. 2018). Globally, rising numbers of individuals who want to have an improved physique and
increasedwell-being revert to the use of IPEDs (Evans-Brown et al. 2012), and particularly amongst
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gym populations (Kimergard and McVeigh 2014). Anabolic-androgenic steroids are a common
IPED and are synthetic derivatives of testosterone, the male sex hormone (Evans 2004; Kicman
2008; McVeigh and Begley 2017; Pope et al. 2014a, 2014b). These substances emulate biological
characteristics of these male hormones thus reproducing the effects on the body, resulting in the
growth of male sexual characteristics and skeletal muscle (Pope and Kanayama 2012; Sagoe et al.
2014a, 2014b; Sobhanian et al. 2013). They are used medically to treat a number of conditions
including protein-calorie malnutrition associated with weight loss, HIV wasting syndrome
(Mulligan and Schambelan 2002), and primary and secondary hypogonadism (Behre et al. 1999;
Nieschlag 2006; Sarosdy 2007; Taylor 2002). The use of AAS for performance-enhancing purposes
amongst athletes has been reported since the 1950s (Hakansson et al. 2012; Hoberman 1992;
Kanayama et al. 2008; Kanayama and Pope 2018; Mottram 2018; Yesalis 2000; Zahnow et al.
2018). Currently, the majority of users of AAS are not competing athletes, with patterns of use
primarily for aesthetic purposes (Begley et al. 2017; Kimergard and McVeigh 2014; Parkinson and
Evans 2006; Pope et al. 2012; Pope et al. 2014a, 2014b; Santos and Coomber 2017). These users
focus primarily on their appearance, body weight, muscle build, and leanness as opposed to their
athletic performance (Hakansson et al. 2012; Parkinson and Evans 2006; Petersson et al. 2010). In
1999, the World Anti-Doping Agency (WADA) was established to monitor drug use (doping) in
sport. The anti-doping code was adopted in 2003 and acts as a framework for sports organisations to
enable them to implement rules, regulations, and policies within sport. WADA and the CODE
protect athlete’s fundamental rights to participate in sport that is doping-free, promotes equality and
fairness for athletes worldwide, and ensures effective detection, deterrence, and prevention programs
are harmonised worldwide (WADA 2019).
There are numerous adverse health consequences that can result from the use of AAS. Of
concern is the long-term morbidity and mortality due to cardiovascular (Baggish et al. 2017)
hepatic (Creagh et al. 1988; Schumacher et al. 1999) and cognitive effects (Bjornebekk et al.
2017; Westlye et al. 2017) of AAS use. Other health consequences include those affecting
other organ systems such as gynaecomastia, acne, hair loss (Pope et al. 2014a, 2014b), and
impaired sexual function (Kanayama and Pope Jr. 2012). Psychological effects of AAS use
include mood disturbances (Kanayama and Pope Jr. 2012) and dependence (Pope et al. 2014a,
2014b). Some of these adverse effects are acute but subside once the use of AAS has ceased.
Chronic conditions can result from the long-term use of these substances (Pope et al. 2014a,
2014b). Lindqvist et al. (2013) reported an association between the past use of AAS and long-
term poorer mental health outcomes. Negative psychological states have also been reported
such as depression, increased aggression, and anxiety (Pope et al. 2005) and with the severity
of these possibly dependent on AAS dosage (Kimergard and McVeigh 2014).
Traditionally AAS for image and performance enhancement have been taken in ‘cycles’.
These regimens involve periods of use of the substances that last 6 to 12 weeks, sometimes
more (Yesalis 2000). Research has indicated an increased cycle (the period that drugs are used)
length whereby users utilise a ‘blast and cruise’ method. This phenomenon is when the user
replaces the ‘off-cycle’ with a period of lower dosage. This has implications for the recovery of
testosterone production and health outcomes (Chandler and McVeigh 2014). Users of AAS
regularly consume a range of substances simultaneously known as ‘stacking’ (Sagoe et al.
2015; Yesalis 2000). The reasons for stacking are an endeavour to achieve synergistic effects
which allows the user to stimulate more receptor sites, thus creating greater anabolic effects
(Duchaine 1989; Nilsson 2001; Yesalis 2000). Additionally, those who inject AAS, which is
the primary route of administration (Bates et al. 2017), are at further risk of harms such as
injecting site wounds, injecting errors such as the incident reported in Jordan in 2002, which
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was associated with the death of a 22 year old (Boulad 2003), bacterial and fungal infections in
the event of sharing injecting equipment, and the transmission of blood borne viruses (ACMD
2010; Bates et al. 2017; Bates and McVeigh 2016). Appropriate harm reduction interventions
targeting AAS users are crucial to preventing these adverse outcomes (Glass et al. 2019).
In terms of prevalence of this phenomenon, Sagoe and Pallesen (2018) have suggested that
AAS use is generally recorded as more prevalent in Western countries, Brazil and the Middle
East, and less widespread in Asia and Africa. Studies carried out in Eastern Mediterranean
countries indicate that the use of AAS, whilst low, is on the rise and therefore a growing
concern. Hence, we conducted a scoping review of extant empirical literature to describe and
map what is known about the relatively new phenomenon of AAS use in the Eastern
Mediterranean.
Methods
Scoping reviews are increasingly utilised as independent research methodologies to
address broader research questions in comparison to systematic reviews (Arksey and
O’Malley 2005; Khalil et al. 2016; Levac et al. 2010; Peters et al. 2015). They are
usually conducted to identify gaps in knowledge, examine the extent (i.e. size), range
(i.e. variety), and nature (i.e. characteristics) of the evidence on a certain topic or
question (in this case, AAS use in the Eastern Mediterranean), summarise findings from
a heterogeneous body of knowledge, or set agendas for future research and policy
directives (Arksey and O’Malley 2005; Brandt et al. 2014; Daudt et al. 2013; Levac
et al. 2010; Tricco et al. 2016). Scoping reviews are defined by Tricco et al. (2016) as ‘a
type of knowledge synthesis, follow a systematic approach to map evidence on a topic
and identify main concepts, theories, sources, and knowledge gaps.’
We adhered to Arksey and O’Malley’s (2005) five stage iterative process scoping review
methodology. These stages included the following: (1) identifying the essential research
question, (2) identifying relevant studies, (3) study selection, (4) charting the data, and (5)
collecting, summarising, and reporting the results. The process was underpinned by the
research question (What do we know about AAS use in the Eastern Mediterranean region?)
and reviewed all available published empirical literature in the English language on this topic.
There was no restriction on date. To enable the broadest picture of current knowledge and
perceptions relating to this issue, we included policy documents and international and national
reports, online reports, conference proceedings, commentary pieces, and editorials, in addition
to articles in scholarly peer reviewed journals. The search was implemented in April 2019. We
used the following databases: Web of Science; Cochrane Library; MEDLINE; PsycINFO;
SPORTDiscus; Social Science Citation Index; Conf Proceedings Citation index; PubMED;
Science Direct; and Researchgate. A thorough list of key search terms used in AAS research
articles known to the research team (who had public health, addiction, and clinical specialisms)
informed the search strategy (see Table 1).
Eligibility criteria focused on use of AAS in Eastern Mediterranean Countries, i.e. Afghan-
istan, Bahrain, Djibouti, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon,
Libyan Arab Jamahiriya, Morocco, Oman, Pakistan, Qatar, Saudi Arabia, Somalia, Sudan,
Syrian Arab Republic, Tunisia, United Arab Emirates, and Yemen (WHO, 2019). Inclusion
and exclusion criteria were discussed and agreed with all members of the research team.
Clinical case reports, case series, and laboratory analysis only studies were excluded. The
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initial search identified 477 articles; and following initial screening, 355 were removed for lack
of relevance, with the remaining 122 screened for inclusion in the study. Finally, duplicates
(n = 51) and further records excluded for lack of relevance were removed (n = 32), leaving 39
records in total (see Fig. 1).
The 39 records were charted and thematically analysed, as per Arksey and O’Malley
(2005). A table was created using Microsoft Word to chart relevant data (year of
publication, author, location, method and aim, key findings, and conclusion) and to
analyse the extracted data thematically to identify commonalities, emergent issues, and
gaps in the literature. A trial charting exercise of several records was conducted by the
lead author as recommended by Daudt et al. (2013). This was followed by a team
consultation to ensure consistency with the research question and the scoping review
aim, and to identify prior categories to support further data extraction and charting. The
textual dataset was re-read numerous times by author one to gain familiarity with the
data and identify and code emerging themes. The charted data was analysed and
systematised by thematic manual coding, which organised the data and subsequently
structured into themes through patterns identified in associated categories (Crossley




anabolic steroids OR anabolic-androgenic OR anabolic hormones OR performance
enhancing OR doping OR image enhancing OR IPED OR PIED OR PED OR PEA
Muscle sport OR athletes OR muscle OR gym OR fitness OR bodybuild OR weight lift OR
physique OR gymnasium OR commercial club
Middle Eastern
Countries
Middle East OR Eastern Mediterranean OR Arab OR Afghanistan OR Bahrain OR
Djibouti OR Egypt OR Iran OR Iraq OR Jordan OR Kuwait OR Lebanon OR Libya
OR Morocco OR Oman OR Pakistan OR Qatar OR Saudi Arabia OR Somalia OR
Sudan OR Syria OR Tunisia OR United Arab Emirates OR Yemen
Fig. 1 Flow chart of the search strategy used
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2007). Following data analysis, two papers were omitted (Boos et al. 2011; Cassler et al.
2013) as their results showed that n = 0 AAS users were found in their studies, leaving a
final number of 37 included studies in the review (see Fig. 2). Four themes emerged from
the review: (1) profile of AAS users; (2) AAS within gymnasium practice; (3) AAS
regimes of use; and (4) knowledge and understanding of the AAS concept and related
adverse effects.
Results
We included published empirical records on AAS from searches in the twenty-one countries
located in the Eastern Mediterranean region. The types of records included were survey studies
in Saudi Arabia (Al Bishi and Afify 2017; Al Ghobain et al. 2016; Al Nozha and Elshatarat
2017; Alharbi et al. 2019; Althobiti et al. 2018; Bahri et al. 2017; Jabari et al. 2016), United
Arab Emirates (Al-Falasi et al. 2008), Kuwait (Allafi et al. 2019; Alsaeed and Alabkal 2015;
Khullar et al. 2016), Iran (Allahverdipour et al. 2012; Angoorani and Halabchi 2015; Asr et al.
2018; Bordbar et al. 2014; Fijan et al. 2018; Haerinejad et al. 2016; Jalilian et al. 2011;
Kargarfard et al. 2015; Mohammad 2014; Nakhaee et al. 2013; Razavi et al. 2014; Rezaei
2017; Saeidinejat et al. 2017; Sepehri et al. 2009; Sobhanian et al. 2013), Iraq (Boos et al.
2010; Habeeb et al. 2012), Lebanon (Hitti et al. 2014; Melki et al. 2015), Jordan (Tahtamouni
et al. 2008; Wazaify et al. 2014), Pakistan (Hussain et al. 2018; Uddin et al. 2019; Zafar et al.
2018), and Sudan (Khidir and Mahmoud 2018); and conference proceedings from Bahrain
(Alsamani et al. 2017) (see Table 2).
Fig. 2 Updated flow chart following data analysis
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Profile of AAS Users in the Middle East
The quantitative studies from Iran (n = 14), Saudi Arabia (n = 7), Kuwait (n = 4), Leba-
non (n = 2), United Arab Emirates (n = 1), Iraq (n = 2), Jordan (n = 2), Pakistan (n = 3),
Sudan (n = 1), and conference proceedings from Bahrain (n = 1) generated a total of 5425
current and former AAS users. A total of 5371 of these were male and only 6 were
female. Three studies did not detail whether the AAS users were male or female (Boos
et al. 2010; Khidir and Mahmoud 2018; Wazaify et al. 2014) although female partici-
pants were included in their studies. The age range of AAS users ranged from 14 to
60 years old (Al-Falasi et al. 2008; Al Ghobain et al. 2016; Alharbi et al. 2019;
Allahverdipour et al. 2012; Al Nozh & Elshatarat, 2017; Alsaeed and Alabkal 2015;
Althobiti et al. 2018; Angoorani and Halabchi 2015; Asr et al. 2018; Bahri et al. 2017;
Boos et al. 2010; Jabari et al. 2016; Khullar et al. 2016; Bordbar et al. 2014; Fijan et al.
2018; Habeeb et al. 2012; Haerinejad et al. 2016; Hitti et al. 2014; Hussain et al. 2018;
Jalilian et al. 2011; Kargarfard et al. 2015; Khidir and Mahmoud 2018; Melki et al. 2015;
Mohammad 2014; Razavi et al. 2014; Tahtamouni et al. 2008; Uddin et al. 2019;
Wazaify et al. 2014; Zafar et al. 2018). Seven studies did not clearly state age or age
range (Allafi et al. 2019; Alsamani et al. 2017; Nakhaee et al. 2013; Rezaie, 2017;
Saeidinejat et al. 2017; Sepehri et al. 2009; Sobhanian et al. 2013). Participants were
from Iran, Saudi Arabia, United Arab Emirates, Kuwait, Lebanon, Jordan, Iraq, Bahrain,
Pakistan, and Sudan, with no notable differences in age ranges between countries. Those
aged 18–34 years reported using AAS to a greater extent than other age groups (14–17
and 35–59 years). Not all studies reported on background characteristics such as marital
status, employment status, and education. Studies that did report on demographics are
presented in Table 3.
Gymnasium Practice in the Eastern Mediterranean Region
Gymnasium practice was not reported by twenty-one peer reviewed journal papers (Al
Ghobain et al. 2016; Allafi et al. 2019; Al Nozha and Elshatarat 2017; Alsaeed and Alabkal
2015; Alsamani et al. 2017; Althobiti et al. 2018; Asr et al. 2018; Boos et al. 2010, 2011;
Bordbar et al. 2014; Haerinejad et al. 2016; Hitti et al. 2014; Jabari et al. 2016; Kargarfard
et al. 2015; Khullar et al. 2016; Khidir and Mahmoud 2018; Melki et al. 2015; Mohammad
2014; Nakhaee et al. 2013; Saeidinejat et al. 2017; Sobhanian et al. 2013; Tahtamouni et al.
2008). The types of gyms and fitness clubs where AAS were used included gymnastics clubs
(Saudi Arabia), commercial gyms and social clubs (Saudi Arabia, United Arab Emirates, Iraq,
Iran, Pakistan), hotel gyms (United Arab Emirates), private clubs (Saudi Arabia), bodybuilding
clubs (Iran, Saudi Arabia, Kuwait), sports centres (Pakistan), martial arts clubs (Saudi Arabia),
rec centres (Pakistan), and athletic clubs (Iran) (Al Bishi and Afify 2017; Al-Falasi et al. 2008;
Alharbi et al. 2019; Alsamani et al. 2017; Angoorani and Halabchi 2015; Bahri et al. 2017;
Fijan et al. 2018; Habeeb et al. 2012; Haerinejad et al. 2016; Hussain et al. 2018; Jalilian et al.
2011; Kargarfard et al. 2015; Mohammad 2014; Nakhaee et al. 2013; Razavi et al. 2014;
Rezaei 2017; Sepehri et al. 2009; Sobhanian et al. 2013; Tahtamouni et al. 2008; Uddin et al.
2019; Zafar et al. 2018). The remaining fifteen papers did not state the type of settings they
recruited participants from.
Users reported using gymnasia for less than 6 months (n = 31), more than 6 months (n =
165), more than 2 years (n = 107), more than 4 years (n = 54) and one paper reported 11 months
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to 10 years (Jalilian et al. 2011). Users spent between two and five days (n = 75), more than
three days (n = 18), and more than five days (n = 72) per week at their chosen gymnasium.
Reasons for attending a gymnasium included bodybuilding, muscle building, professional
training and daily gym practice (Al Bishi and Afify 2017; Al-Falasi et al. 2008; Alharbi et al.
2019; Althobiti et al. 2018).
Table 3 Background characteristics
Characteristics Country n %
Marital status










Divorced Saudi Arabia 14 2.45
Lebanon 6 1.05
Level of education
Basic education Saudi Arabia 46 6.11
Kuwait 12 5.02

















Technical Lebanon 45 7.91
Employment status










Student Saudi Arabia 236 34.30
UAE 8 23.53
Lebanon 9 1.55
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AAS Regimes of Use in the Eastern Mediterranean Region
Sourcing of AAS was not investigated by more than half of the included studies (Al
Ghobain et al. 2016; Allahverdipour et al. 2012; Al Nozha and Elshatarat 2017; Alsamani
et al. 2017; Angoorani and Halabchi 2015;Asr et al. 2018; Bahri et al. 2017; Bordbar et al.
2014; Fijan et al. 2018; Jabari et al. 2016; Jalilian et al. 2011: Karfargard et al., 2015;
Khullar et al. 2016; Khidir and Mahmoud 2018; Melki et al. 2015; Mohammad 2014;
Razavi et al. 2014; Rezaie, 2017; Saeidinejat et al. 2017; Zafar et al. 2018). However,
research conducted in Saudi Arabia, United Arab Emirates, Kuwait, Iran, Iraq, Lebanon,
Pakistan, and Jordan did report sourcing. Purchasing from friends, gym trainers, and
coaches were the primary sourcing routes in these countries. Other sourcing routes
included sourcing via gym members, training partners, the black market, online purchas-
ing, pharmacists, physicians, veterinary surgeons, fitness stores, and purchasing abroad
and bringing home. One military based study reported sourcing on site (Boos et al. 2010),
i.e. the Contingency Operating Base and the PX retail store on base.
A range of AAS and other IPEDs were reported as being used. Sixteen studies (Al
Bishi and Afify 2017; Allafi et al. 2019; Allahverdipour et al. 2012; Al Nozha and
Elshatarat 2017; Alsaeed and Alabkal 2015; Althobiti et al. 2018; Angoorani and
Halabchi 2015; Asr et al. 2018; Bahri et al. 2017; Hitti et al. 2014; Hussain et al.
2018; Jalilian et al. 2011; Kargarfard et al. 2015; Mohammad 2014; Razavi et al. 2014;
Wazaify et al. 2014) reported on the types of AAS and associated drugs being used. The
most commonly reported injectable were testosterone and nandrolone decanoate, and the
most common oral AAS used were methandrostenolone and stanozolol, with the use of
growth hormone reported in only four studies. Routes of administration (ROA) were
reported in less than half of the studies (Al Bishi and Afify 2017; Allafi et al. 2019;
Alsaeed and Alabkal 2015; Bahri et al. 2017; Habeeb et al. 2012; Hitti et al. 2014;
Hussain et al. 2018; Khullar et al. 2016; Razavi et al. 2014; Wazaify et al. 2014; Zafar
et al. 2018) highlighting injecting as the predominant choice of ROA amongst users.
Sobhanian et al. (2013) did not elaborate on the predominant route but reported both oral
and injecting routes of administration. Their research also interestingly gave detailed
information regarding the person administering the injection of AAS to the user (other
than self) which included coach (n = 9); coach, teammate, or nurse (n = 1); coach or
friend (n = 1); coach or nurse (n = 1); coach or physician (n = 1); physician (n = 4);
teammate (n = 6); teammate or nurse (n = 1); friend (n = 4); family member (n = 1);
another athlete (n = 8).
Duration of AAS use was only reported in a small number of articles (Al Bishi and Afify
2017; Alsamani et al. 2017; Asr et al. 2018; Bahri et al. 2017; Sobhanian et al. 2013) and
ranged from less than 1 month to more than 5 years. One study in Saudi Arabia reported that
69.7% of AAS user participants simply had no knowledge of their duration of AAS use (Jabari
et al. 2016). Twenty-five papers did not report duration of AAS use.
Thirteen studies in United Arab Emirates, Saudi Arabia, Kuwait, Sudan and Iran did
not report on the reasons for AAS use (Al-Falasi et al. 2008; Alharbi et al. 2019; Allafi
et al. 2019; Al Nozha and Elshatarat 2017; Alsaeed and Alabkal 2015; Angoorani and
Halabchi 2015; Althobiti et al. 2018; Bahri et al. 2017; Bordbar et al. 2014; Jalilian et al.
2011; Kargarfard et al. 2015; Khidir and Mahmoud 2018; Razavi et al. 2014). Reasons
for use of AAS were largely stated as being to improve image, appearance, and overall
physique; to increase muscle mass and improve strength and power; achieve
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‘attractiveness’; to improve athletic performance; to increase chances of winning body-
building competitions; to increase self-confidence and social recognition; and due to
advice or recommendation from friends, trainers, and physicians. Other less predominant
reasons for use were to increase sex drive, weight gain, fat burning, aid recovery,
unspecified medical reasons, and to enhance energy.
The adverse effects of AAS use were not investigated by all studies, with twenty-four
papers not reporting on these effects. Self-reported effects by the remaining studies in Kuwait,
Bahrain, Saudi Arabia, Iran, and Jordan were aggression, depression, sexual problems,
increased appetite, acne, hair loss, gynecomastia, mood changes, fluid retention, headaches,
increased hair growth, cardiovascular problems, psychiatric issues, and hepatic and renal
damage (Allafi et al. 2019; Alsamani et al. 2017; Althobiti et al. 2018; Bahri et al. 2017;
Haerinejad et al. 2016; Hussain et al. 2018; Razavi et al. 2014; Tahtamouni et al. 2008; Uddin
et al. 2019; Wazaify et al. 2014). The study by Habeeb et al. (2012) stated that most AAS users
reported the use of only dietary supplements initially, but on recommendation of others,
initiated the use of AAS to improve performance.
Knowledge and Understanding of the AAS Concept and Adverse Effects
Studies included in this review reported on user’s knowledge of the AAS ‘concept’ (i.e.
their understanding of and expected outcomes of AAS use). Thirteen studies in Kuwait,
Iran, Iraq, and Jordan did not examine user’s knowledge and understanding of either AAS
concept or adverse effects (Allafi et al. 2019; Allahverdipour et al. 2012; Angoorani and
Halabchi 2015; Asr et al. 2018; Boos et al. 2010; Fijan et al. 2018; Habeeb et al. 2012;
Hussain et al. 2018; Jalilian et al. 2011; Khullar et al. 2016; Sepehri et al. 2009; Sobhanian
et al. 2013; Tahtamouni et al. 2008). It was noted that most participants in these Eastern
Mediterranean countries were aware of the anabolic effects of AAS such as increased
muscle mass, bodybuilding effects, increased in body weight, and increased muscle
strength (Al Bishi and Afify 2017; Al-Falasi et al. 2008; Mohammad 2014). In relation
to adverse effects, several papers in Saudi Arabia, United Arab Emirates, Kuwait, and Iran
reported an inadequate level of self-reported knowledge overall amongst participants (Al
Bishi and Afify 2017; Al-Falasi et al. 2008; Alharbi et al. 2019; Alsaeed and Alabkal
2015; Althobiti et al. 2018; Bahri et al. 2017; Jabari et al. 2016; Khidir and Mahmoud
2018; Mohammad 2014; Rezaei 2017; Uddin et al. 2019; Wazaify et al. 2014; Zafar et al.
2018). Less than half of the participants of the study by Al-Falasi et al. (2008) in the
United Arab Emirates had any knowledge of either physical or psychological adverse
effects A high number of participants of the study by Alharbi et al. (2019) in Saudi Arabia
answered ‘I don’t know’ when also asked about their awareness of these adverse effects.
Haerinejad et al. (2016) reported that the majority of participants had no knowledge of
adverse effects prior to use. One study reported that although users (n = 16) had knowledge
of adverse effects, they continued to use AAS (Kargarfard et al. 2015).
One study reported that overall, it was believed that the benefits of ASS on muscle growth
outweighed its adverse harmful effects (Alsaeed and Alabkal 2015). Bordbar et al.’s (2014)
study in Iran found that a small number of participants believed that athletes should be allowed
to use AAS for athletic performance. Jabari et al. (2016) in Saudi Arabia found that 77% of
participants who self-declared knowledge of the adverse effects of AAS would still recom-
mend them to friends. Hitti et al. (2014) noted that users of AAS were more likely to consume
alcohol daily than non-AAS users.
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Discussion
We present here the first known attempt to map and describe extant literature on the use of
AAS in the Eastern Mediterranean, an emergent phenomenon in the region, and one which we
speculate is at early stages of diffusion. Countries where publications were located include
Saudi Arabia, United Arab Emirates, Kuwait, Iran, Iraq, Lebanon, Jordan, Bahrain, Afghan-
istan, Pakistan, and Sudan. Whilst we adhere to the robust Arksey and O Malley protocol for
scoping review, we recognise that this review is compromised due to the following limitations.
Firstly, only empirical studies were included in the search and investigative journalist reports
were not included thus limiting the scope. Secondly, some studies were undertaken in the same
country, whereby we do not know if individuals participated in more than one survey, creating
a potential overlap, and over estimation of numbers of AAS users. Thirdly, it is unclear as to
whether participants were citizens of these countries or whether they were foreigners from
other more Westernised cultures. Western influences potentially impact on a country’s body
ideals, perceptions of masculinity, popularity of exercise and experimentation, and use of
enhancement drugs. Religion or faith of the participants was not asked; therefore, we cannot
assume that participants are of the Islamic faith. Lastly, some studies did not provide extensive
detail on all countries participating in their surveys. Hence, this scoping review should be
viewed with caution as it cannot provide an accurate contemporary interpretation of AAS use
in the Eastern Mediterranean region. It does however give us insight into the phenomenon at
early stages of diffusion with regard to rationales for use, knowledge around use, regimes,
locations of use, and sourcing routes.
The use of AAS for performance and image enhancement is a growing concern in these
countries; however, knowledge, understanding, and awareness of health harms related to AAS
appear to be varied and somewhat limited. Most studies in this review reported AAS users as
single and in fulltime employment, highlighting high rates of employment, similar to studies in
the UK (Baker et al. 2008; Begley et al. 2017; Greenway and Price 2018), Australia (Jacka
et al. 2017), and the USA (Pope et al. 2014a, 2014b). Educational status of AAS current and
former users in the Middle East was highest in the ‘higher education’ range which corroborates
research in Australia (Cohen et al. 2007) and the USA (Westerman et al. 2016). Duration of the
use of AAS was underreported overall; the maximum length of use reported was 5 years,
indicating that the use of AAS amongst some gym populations in the Middle East is clearly
established. However, when compared with studies in the UK (Baker et al. 2008; Begley et al.
2017; Greenway and Price 2018), Australia (Jacka et al. 2017), and the USA (Pope et al.
2014a, 2014b), it is evident that this phenomenon is at an early stage of diffusion. This has
implications for design of culturally appropriate health-related interventions underpinned by
harm reduction and cessation supports in the Eastern Mediterranean. We underscore implica-
tions for normalisation of this form of enhancement drug use amongst athletes and gym goers
(Mulrooney et al. 2019), with this review providing a key starting point for interventions prior
to normalisation of use. There is growing evidence of the possibility of deleterious effects of
long-term AAS use on the health of a user’s brain (Bjornebekk et al. 2017) and cognitive
defects in long-term high dose users (Kanayama et al. 2013).
Research has indicated that factors contributing to decisions to use AAS include beliefs and
personal traits (Bates et al. 2018). Building muscle and enhancing physique and training
aspects were the primary reasons for gymnasium attendance amongst individuals reporting
AAS use in the Eastern Mediterranean. Some less predominant reasons for AAS use centred
on desire to increase sex drive, weight gain, fat burning, help improve an injury, medical
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reasons, and for more energy. Literature shows that AAS are used for the improvement of
physique, increased muscle mass, strength enhancement, and athletic performance enhance-
ment (Begley et al. 2017; Brennan et al. 2016; Ip et al. 2011; Ip et al. 2015; Zahnow et al.
2018). Masculinity is a social construct, as is femininity, and is associated with specific values
and cultural contexts (Darwish, 2009). The review suggests that AAS use is overwhelmingly
male indicating the presence of this masculine culture, with only a small number of studies
reporting female use. This largely reflects the evidence from established literature outside the
Eastern Mediterranean, where female use exists at much lower levels than male use and is
characterised by stigma and secrecy (Chandler and McVeigh 2014; Ip et al. 2010; Sagoe et al.
2014a, 2014b) but to a lesser extent than males (Brennan et al. 2016).
We recognise that gender and religiosity are symbiotic in their relationship in that religious
symbolism facilitates the male ego (Aslam 2012). In other countries, men have a higher
prevalence of AAS use than females for example in the USA (Kashkin and Kleber 1989;
Tokish et al. 2004; Yesalis 2001), UK (Begley et al. 2017), Poland (Rachoń et al. 2006), and
Sweden (Lindqvist et al. 2013), and as such, these findings reflect gender differences in use
found in other countries. Islamic faith however prohibits intoxication from alcohol and the use
of substances or behaviours that induce addiction such as illicit drugs or gambling (Crabtree
et al. 2017; Salaymeh 2015). As mentioned earlier, we do not have participant profile in terms
of their citizenship or religiosity. Van Hout and Kean (2015) reported that male Muslim users
of AAS and other IPEDs in the UK felt these substances led them to be in control of and
promoted their perceptions of their physical and spiritual health, and were not harmful, thus
circumventing religious parameters. In addition, we recognise that use of AAS in Islamic faith
is discouraged and the legality of AAS is unclear in some Eastern Mediterranean countries
where regulatory controls are complex and varied. Of interest is that one study, namely,
Angoorani and Halabchi (2015) observed a 25% prevalence of AAS use in their all-female
study. This is perhaps indicative of the lower proportion of females attending mainstream gyms
(and commonly not attending male gyms) in the included studies (Donnelly et al. 2018).
Users of AAS had some knowledge of the anabolic effects of AAS and the overall AAS
‘concept’ such as increased muscle mass, bodybuilding effects, and increased power and muscle
strength. There was however a concerning and inadequate level of knowledge around adverse
effects and health problems (Al Bishi and Afify 2017; Al-Falasi et al. 2008; Alharbi et al. 2019;
Alsaeed and Alabkal 2015; Bahri et al. 2017; Jabari et al. 2016; Rezaei 2017). Aggression is a
reported adverse psychological effect of AAS use (Bahrke et al. 1996; Bahrke et al. 1990; Pope et al.
2000). Lack of knowledge on such adverse effects is not uncommon and has also been reported in
studies in Australia (Yager and O’Dea 2014), Sweden (Nilsson et al. 2005), and the USA (Hoffman
et al. 2008). Worldwide, enhanced levels of awareness and knowledge are warranted to support
choices to use safely (Nilsson et al. 2005). Of those that includedROA in their surveys, injectingwas
reported as the predominant route of administration. This may indicate presence of only a small
cohort of oral AAS users (similar to recent research by van de Ven et al. (2019)). Blood-borne virus
(BBV) transmission associated with any form of injecting drug use is a major public health concern
(Hearne et al. 2016; Hope et al. 2013; VanHout 2014). Of notewas that questions relating to sharing
of injecting equipment or knowledge and awareness of blood-borne virus (BBV) transmission were
not asked in the included records. Some records did however refer to the injection of the user by gym
trainers; however, harms that may result from this practicewere also not investigated further. Of note
is the limited reference to support from healthcare professionals to this community. Clearly, there is a
role for health professionals in relation to prevention and harm reduction with the potential for
pharmacists to take the leading role.
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Lastly, sourcing of AAS was reported in a limited number of studies and highlighted how
AAS users are highly influenced by availability in gym settings and by coaches and trainers.
Some reported being recommended to use AAS by them (Razavi et al. 2014; Fijan et al. 2018)
and also sourcing their AAS from them, which supports similar research elsewhere (Fincoeur
et al. 2015; Maycock and Howat 2007; Santos and Coomber 2017), given that AAS and
associated drugs are illicitly manufactured and sourced (Begley et al. 2017) via routes such as
online marketplaces and online private sellers (Brennan et al. 2016), and with low resource
countries increasingly involved in manufacture and as transit routes(Evans-Brown et al. 2009).
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